250 related articles for article (PubMed ID: 17940115)
1. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.
Park JY; Chong AY; Cochran EK; Kleiner DE; Haller MJ; Schatz DA; Gorden P
J Clin Endocrinol Metab; 2008 Jan; 93(1):26-31. PubMed ID: 17940115
[TBL] [Abstract][Full Text] [Related]
2. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
[TBL] [Abstract][Full Text] [Related]
3. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P
J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
[TBL] [Abstract][Full Text] [Related]
4. [Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].
Jazet IM; Jonker JT; Wijngaarden MA; Lamb H; Smelt AH
Ned Tijdschr Geneeskd; 2013; 157(4):A5482. PubMed ID: 23343738
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of leptin therapy in the different forms of human lipodystrophy.
Chong AY; Lupsa BC; Cochran EK; Gorden P
Diabetologia; 2010 Jan; 53(1):27-35. PubMed ID: 19727665
[TBL] [Abstract][Full Text] [Related]
6. Consequences of stopping and restarting leptin in an adolescent with lipodystrophy.
Kamran F; Rother KI; Cochran E; Safar Zadeh E; Gorden P; Brown RJ
Horm Res Paediatr; 2012; 78(5-6):320-5. PubMed ID: 22965160
[TBL] [Abstract][Full Text] [Related]
7. Leptin-replacement therapy for lipodystrophy.
Oral EA; Simha V; Ruiz E; Andewelt A; Premkumar A; Snell P; Wagner AJ; DePaoli AM; Reitman ML; Taylor SI; Gorden P; Garg A
N Engl J Med; 2002 Feb; 346(8):570-8. PubMed ID: 11856796
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature.
Misra A; Garg A
Medicine (Baltimore); 2003 Mar; 82(2):129-46. PubMed ID: 12640189
[TBL] [Abstract][Full Text] [Related]
9. Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy.
Oral EA; Javor ED; Ding L; Uzel G; Cochran EK; Young JR; DePaoli AM; Holland SM; Gorden P
J Clin Endocrinol Metab; 2006 Feb; 91(2):621-8. PubMed ID: 16317060
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
[TBL] [Abstract][Full Text] [Related]
11. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.
Nguyen ML; Sachdev V; Burklow TR; Li W; Startzell M; Auh S; Brown RJ
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4327-e4339. PubMed ID: 34223895
[TBL] [Abstract][Full Text] [Related]
12. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.
Javor ED; Cochran EK; Musso C; Young JR; Depaoli AM; Gorden P
Diabetes; 2005 Jul; 54(7):1994-2002. PubMed ID: 15983199
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome.
Lungu AO; Zadeh ES; Goodling A; Cochran E; Gorden P
J Clin Endocrinol Metab; 2012 Feb; 97(2):563-7. PubMed ID: 22090274
[TBL] [Abstract][Full Text] [Related]
15. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
Diker-Cohen T; Cochran E; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
[TBL] [Abstract][Full Text] [Related]
16. A case of generalized lipodystrophy-associated progeroid syndrome treated by leptin replacement with short and long-term monitoring of the metabolic and endocrine profiles.
Fukaishi T; Minami I; Masuda S; Miyachi Y; Tsujimoto K; Izumiyama H; Hashimoto K; Yoshida M; Takahashi S; Kashimada K; Morio T; Kosaki K; Maezawa Y; Yokote K; Yoshimoto T; Yamada T
Endocr J; 2020 Feb; 67(2):211-218. PubMed ID: 31708526
[TBL] [Abstract][Full Text] [Related]
17. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.
Lebastchi J; Ajluni N; Neidert A; Oral EA
J Clin Endocrinol Metab; 2015 Nov; 100(11):3967-70. PubMed ID: 26390101
[TBL] [Abstract][Full Text] [Related]
18. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
Brown RJ; Oral EA; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Gorden P
Endocrine; 2018 Jun; 60(3):479-489. PubMed ID: 29644599
[TBL] [Abstract][Full Text] [Related]
19. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy.
Oral EA; Gorden P; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Brown RJ
Endocrine; 2019 Jun; 64(3):500-511. PubMed ID: 30805888
[TBL] [Abstract][Full Text] [Related]
20. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy.
Javor ED; Moran SA; Young JR; Cochran EK; DePaoli AM; Oral EA; Turman MA; Blackett PR; Savage DB; O'Rahilly S; Balow JE; Gorden P
J Clin Endocrinol Metab; 2004 Jul; 89(7):3199-207. PubMed ID: 15240593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]